A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
24actual
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-08 | actual | When the study began enrolling |
| Primary completion | 2025-05-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-15 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-382
- Drug: ABBV-382
- Drug: Placebo for ABBV-382
- Drug: Placebo for ABBV-382
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Up to Approximately Day 140
Maximum Observed Serum Concentration (Cmax) of ABBV-382
measured Up to Day 112
Time to Cmax (Tmax) of ABBV-382
measured Up to Day 112
Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-382
measured Up to Day 112
Area Under the Serum Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-382
measured Up to Day 112
Terminal Phase Elimination Rate Constant (β) of ABBV-382
measured Up to Day 112
Terminal Phase Elimination Half-Life (t1/2) of ABBV-382
measured Up to Day 112
Anti-Drug Antibody (ADA) of ABBV-382
measured Up to Day 112
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed